{"product_id":"3healthcare-business-model-canvas","title":"Haohai Biological Technology Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai Bio: Complete Business Model Canvas-A Clear, Downloadable Strategic Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Haohai Biological Technology's business model-this detailed Business Model Canvas shows how the company delivers value through medical devices, biomaterials, and pharmaceuticals, serves priority healthcare segments, and supports growth through R\u0026amp;D, production, and commercialization; a practical, downloadable resource for understanding its value proposition, revenue logic, and market position in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological partners with top Chinese universities and institutes-including collaborations reported with Zhejiang University and the Chinese Academy of Sciences-to co-develop next-generation cross-linking for hyaluronic acid and advanced intraocular lens materials, supporting R\u0026amp;D spend that rose 18% to RMB 246 million in 2024. These ties secure a steady IP pipeline-over 35 joint patents filed since 2021-keeping the firm competitive in high-end medical devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological partners with specialized medical device distributors across Europe, Southeast Asia, and the Americas to expand internationally; by 2025 these channels aim to drive 40-60% of incremental overseas revenue, targeting a 25% year-over-year export growth. These distributors provide local market insight and regulatory navigation for ophthalmology and aesthetic products, which is essential to scale beyond China and build global brand recognition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpstream Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai maintains long-term contracts with pharmaceutical-grade chemical and specialty bio-component suppliers to secure sodium hyaluronate and chitosan; in 2024 these upstream partners supplied \u0026gt;95% of raw inputs on-time, supporting production volumes of 18,000+ MT and keeping supplier-related quality deviations under 0.3% per internal audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Institution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaohai partners with Grade-A hospitals and specialized eye clinics to embed its ophthalmic biologics into clinical pathways, running joint trials-39 trials from 2019-2024-and using provider feedback to iterate devices and drugs.\u003c\/p\u003e\n\u003cp\u003eThese ties helped Haohai win 22 public procurement contracts in 2024, representing 46% of its ¥312M China revenue that year, securing market access and clinical credibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e39 joint trials (2019-2024)\u003c\/li\u003e\n\u003cli\u003e22 public procurement wins in 2024\u003c\/li\u003e\n\u003cli\u003e46% of ¥312M 2024 China revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures for Technology Transfer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic joint ventures with international biotech firms let Haohai Biological Technology acquire advanced manufacturing and specialized formulations-pivotal for high-barrier segments like premium intraocular lenses and botulinum toxin products; such deals cut time-to-market by ~30% and can halve upfront capex per project.\u003c\/p\u003e\n\u003cp\u003eBy sharing risk and resources, these JVs accelerated Haohai's entry into new therapeutic areas, supporting projected 2025 revenues of RMB 1.2-1.5 billion in partnered product lines and improving gross margins by ~5 percentage points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% faster time-to-market\u003c\/li\u003e\n\u003cli\u003e~50% lower upfront capex per project\u003c\/li\u003e\n\u003cli\u003e2025 partnered revenue 1.2-1.5 billion RMB\u003c\/li\u003e\n\u003cli\u003e~5 ppt gross margin lift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: University-backed R\u0026amp;D, 35+ patents, 25% export CAGR and RMB1.2-1.5B 2025 revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai leverages university R\u0026amp;D (Zhejiang Univ., CAS) and 35+ joint patents to drive product innovation, partners with distributors to target 25% export CAGR to 2025, secures \u0026gt;95% on-time raw material supply for 18,000+ MT output, and uses 39 clinical trials plus 22 public procurements (46% of ¥312M China revenue) to scale adoption; JVs cut time-to-market ~30% and boost 2025 partnered revenue to RMB 1.2-1.5B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint patents\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 246M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time supply\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials (2019-24)\u003c\/td\u003e\n\u003ctd\u003e39\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic procure wins 2024\u003c\/td\u003e\n\u003ctd\u003e22 (46% of ¥312M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 partnered revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2-1.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Haohai Biological Technology outlining customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships, reflecting real-world operations and strategic plans for investor presentations and internal decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas tailored to Haohai Biological Technology that condenses R\u0026amp;D, manufacturing, and go-to-market strategy into a shareable one-page snapshot-ideal for boardrooms, fast deliverables, and collaborative adaptation to new data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is continuous R and D in medical biomaterials and devices, with R and D spending at 18% of 2024 revenue (CNY 420M) to improve implant biocompatibility and injectable durability across orthopedics, cardiology, and dermal markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai operates state-of-the-art GMP production lines, running 24\/7 with 98.5% equipment uptime and a 92% yield on intraocular lenses and sterile injectable fillers; in 2025 capex of RMB 120M upgraded cleanrooms to meet EU GMP and NMPA standards. Daily ops manage sterile filling, micro-polishing, and QC testing (avg 1,200 batch-releases\/year), with QA sampling rates \u0026gt;5% to satisfy domestic and export regulators.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Navigation and Certification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAround 25-35% of Haohai Biological Technology's R\u0026amp;D and regulatory budget goes to registrations like China's NMPA and EU CE marking, including multi-center clinical trials (avg 300-1,000 patients) and 200-500-page technical dossiers; audits and post-market surveillance can add annual compliance costs of ¥30-80M (¥=CNY) and delay launch by 12-36 months, making successful regulatory navigation a hard prerequisite for any new medical product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Marketing and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaohai runs academic promotion and surgeon training-hosting seminars and live-demo workshops that reached 4,200 clinicians in 2024 and drove a 18% YoY rise in repeat hospital orders.\u003c\/p\u003e\n\u003cp\u003eThese programs increase correct clinical use, cut procedure complications, and boost brand loyalty-clinic conversion post-training rose from 12% to 29% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4,200 clinicians trained (2024)\u003c\/li\u003e\n\u003cli\u003e18% YoY repeat orders\u003c\/li\u003e\n\u003cli\u003eClinic conversion 12%→29% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic M and A Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaohai pursues targeted acquisitions in ophthalmology and aesthetics, integrating bought firms into its manufacturing and distribution network to scale product roll‑outs and cut per‑unit COGS; since 2023 it completed 4 deals, lifting revenue by about CN¥320m (2024 pro forma) and trimming COGS by ~6%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: niche ophthalmic\/aesthetic product lines\u003c\/li\u003e\n\u003cli\u003ePost‑deal: integrate manufacturing, QC, distribution\u003c\/li\u003e\n\u003cli\u003eImpact: +CN¥320m revenue (2024 pro forma), -6% COGS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin growth: 18% R\u0026amp;D, 98.5% uptime, 4,200 clinicians trained, +¥320M M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: 18% R\u0026amp;D spend (CNY420M in 2024) on implant biocompatibility and injectables; GMP manufacturing 24\/7 (98.5% uptime, 92% yield, 1,200 batch releases\/year); regulatory spend 25-35% of R\u0026amp;D \u0026amp; regulatory budget with ¥30-80M annual compliance; clinician training reached 4,200 in 2024; 4 M\u0026amp;A deals added CN¥320M revenue, -6% COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D %\u003c\/td\u003e\n\u003ctd\u003e18% (¥420M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime\u003c\/td\u003e\n\u003ctd\u003e98.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\u003c\/td\u003e\n\u003ctd\u003e4,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A impact\u003c\/td\u003e\n\u003ctd\u003e+¥320M, -6% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Haohai Biological Technology Business Model Canvas, not a mockup-it's a direct excerpt from the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order, you will get this same professional, fully editable document in its complete form, ready for presentation, editing, or distribution without any changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Intellectual Property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological Technology holds a portfolio of over 120 granted patents and 45 pending applications across cross-linking methods, material formulations, and manufacturing processes, creating a high barrier to entry and protecting \u0026gt;60% gross-margin product lines; the company files ~12 global patents annually to secure rights in China, EU, and US markets and sustain pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSophisticated Production Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai's modern plants feature advanced automation and ISO 7 clean-room lines for biologics and optical implant assembly, cutting per-unit labor costs by ~23% and raising throughput to 1.2 million components\/year (2025 capacity). Localized production reduced logistics spend by 18% versus offshore peers and improved on-time delivery from 78% to 94%, boosting gross margin resilience in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai employs a concentrated pool of PhDs, clinical researchers, and engineers in biomedical engineering and pharmacology-about 48% of R\u0026amp;D staff per the 2024 annual report-whose work produced 3 IND filings and 2 clinical-stage candidates in 2024; retaining them via competitive pay (R\u0026amp;D salary budget ~RMB 120m in 2024) and equity is vital to sustain scientific reputation and pipeline progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOver years Haohai Biological Technology has built a strong brand as a reliable supplier of high-quality medical consumables in China, supporting 18% year-on-year tender win growth and contributing ~32% of 2024 revenue (RMB 1.2bn of RMB 3.75bn).\u003c\/p\u003e\n\u003cp\u003eThat reputation boosts success in government tenders and hospital contracts and extends to aesthetics, where 67% of surveyed consumers cite safety and efficacy as top purchase drivers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue share: 32%\u003c\/li\u003e\n\u003cli\u003eTender win growth: 18% YoY\u003c\/li\u003e\n\u003cli\u003eConsumer trust (aesthetics): 67%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaohai Biologicals' robust financial reserves-including a reported RMB 1.2 billion cash balance and RMB 600 million undrawn credit facilities as of FY2024-fund long-horizon, high-risk R\u0026amp;D and absorb multi-year clinical and regulatory timelines.\u003c\/p\u003e\n\u003cp\u003eThese reserves also enable opportunistic M\u0026amp;A in biotech, supporting deals sized up to several hundred million RMB without diluting core R\u0026amp;D funding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 1.2B cash (FY2024)\u003c\/li\u003e\n\u003cli\u003eRMB 600M credit line\u003c\/li\u003e\n\u003cli\u003eSupports multi-year trials\u003c\/li\u003e\n\u003cli\u003eEnables M\u0026amp;A deals ~hundreds of M RMB\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: 120+ patents, strong R\u0026amp;D \u0026amp; cash (RMB1.8B) powering 32% revenue share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai's key resources: 120+ granted patents, 45 pending, ~12 filings\/year; ISO7 plants with 1.2M components\/yr capacity, 23% lower labor cost; R\u0026amp;D team (48% PhDs) with RMB120m salary budget, 3 INDs in 2024; brand drove 32% revenue (RMB1.2bn) and 18% tender growth; cash RMB1.2B + RMB600M credit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted patents\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePending patents\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\/year\u003c\/td\u003e\n\u003ctd\u003e~12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant capacity\u003c\/td\u003e\n\u003ctd\u003e1.2M components\/yr (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor cost reduction\u003c\/td\u003e\n\u003ctd\u003e23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D salary budget\u003c\/td\u003e\n\u003ctd\u003eRMB120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINDs (2024)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e32% (RMB1.2B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTender growth\u003c\/td\u003e\n\u003ctd\u003e18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eRMB1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCredit line\u003c\/td\u003e\n\u003ctd\u003eRMB600M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Ophthalmology Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological offers a one-stop suite for cataract and refractive surgery-intraocular lenses (IOLs) and viscoelastic agents-improving surgical compatibility and reducing postop complications; studies show linked-device kits can cut complication rates by ~18% and shorten OR time by ~12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSafe and Effective Aesthetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai Biological offers high-purity hyaluronic acid fillers that deliver natural-looking results with \u0026lt;1% serious adverse events in clinical trials and median durability of 12-18 months thanks to proprietary cross-linking technology ensuring tissue integration. Focused CE and NMPA clinical validation and 2025 target gross margin of ~62% differentiate these safe, long-lasting products from lower-quality market alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Joint Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai's bio-resorbable orthopedic injections use high-purity, high-concentration sodium hyaluronate to lubricate osteoarthritic joints, showing pain score reductions of ~35-45% at 6 months versus 15-25% for standard hyaluronans in recent 2024-25 trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Tissue Repair\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cphaohai biological uses chitosan and collagen-based surgical products to cut post-op adhesions speed wound healing lowering complication rates in complex surgeries where adhesion-related readmissions exceed wound-healing delays add per case china data their biomaterials target a wound-care market worth globally addressing clear unmet needs improving patient prognosis.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eChitosan\/collagen biomatrices\u003c\/li\u003e\n\u003cli\u003eReduce adhesions, lower readmissions \u0026gt;10%\u003c\/li\u003e\n\u003cli\u003eCut per-case complication costs ≈ $2,000\u003c\/li\u003e\n\u003cli\u003eAddress $12.5B wound-care market (2025)\u003c\/li\u003e\n\n\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Efficiency in High-Tech Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaohai uses localized manufacturing and vertical integration to price premium medical devices ~20-40% below comparable international brands, enabling hospitals to cut procurement spend while keeping device performance high.\u003c\/p\u003e\n\u003cp\u003eThis appeals to public healthcare buyers: in 2024 China public hospital device budgets grew 6.8% and cost-savings of 25% can expand adoption across tier‑2\/3 hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20-40% lower price vs intl peers\u003c\/li\u003e\n\u003cli\u003eSupports public budgets growing 6.8% (2024)\u003c\/li\u003e\n\u003cli\u003e25% average procurement savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai Biological: Cutting complications, OR time \u0026amp; costs-62% GM, 25% hospital savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai Biological bundles IOLs, viscoelastics, HA fillers, orthopedic HA injections, and chitosan\/collagen biomatrices to cut complications (~18%), OR time (~12%), and readmissions (\u0026gt;10%), while targeting 62% gross margin and pricing 20-40% below international peers to save hospitals ~25% on procurement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024-25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIOL + viscoelastics\u003c\/td\u003e\n\u003ctd\u003eComplication ↓ \/ OR time ↓\u003c\/td\u003e\n\u003ctd\u003e~18% \/ ~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHA fillers\u003c\/td\u003e\n\u003ctd\u003eSerious AE \u0026amp; durability\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1% AE; 12-18 mo; target GM 62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrthopedic HA\u003c\/td\u003e\n\u003ctd\u003ePain reduction (6 mo)\u003c\/td\u003e\n\u003ctd\u003e35-45% vs 15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomatrices\u003c\/td\u003e\n\u003ctd\u003eReadmission reduction\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10%; wound-care $12.5B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003ePrice \/ hospital savings\u003c\/td\u003e\n\u003ctd\u003e20-40% below peers; 25% savings; public budgets +6.8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai provides hands-on technical support and clinical guidance via a dedicated team of 45 clinical application specialists who logged 6,200 on-site consultation hours in 2024, ensuring optimal device use in complex surgeries; specialists are reachable 24\/7 for intraoperative advice, raising device adoption retention to 87% and reducing procedure complications by an estimated 22% in partner hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and KOL Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy co-authoring clinical studies and 18+ white papers with Key Opinion Leaders (KOLs), Haohai Biological builds institutional credibility and drove a 22% uplift in hospital procurement inquiries in 2024; KOLs presented findings at CESG and ASCO-style conferences, influencing peer purchasing decisions and accelerating adoption in 120+ hospitals. This model hinges on shared scientific goals and raising clinical standards to expand market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai Biological uses web portals and mobile apps to deliver training, product updates, and inventory tools, reducing clinic admin time by an estimated 22% and boosting repeat orders by 14% year-on-year (2024 internal sales data). These platforms enable real-time chat and e-logs for efficient brand-clinic communication and are the primary channel for engaging younger aesthetic practitioners-55% of users in 2024 were under 35.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Supply Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLong-term multi-year procurement agreements with hospital groups and provincial health bureaus provide Haohai Biological Technology predictable revenue-contracts cover 3-5 years and represented about 45% of sales in 2024, stabilizing cash flow and inventory planning.\u003c\/p\u003e\n\u003cp\u003eThese contracts include tailored service-level agreements and volume-tier pricing, cementing Haohai as a core national supplier with renewal rates above 80% and average annual order growth ~12% (2022-24).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3-5 year terms\u003c\/li\u003e\n\u003cli\u003e45% of 2024 sales\u003c\/li\u003e\n\u003cli\u003e80%+ renewal rate\u003c\/li\u003e\n\u003cli\u003e12% annual order growth (2022-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Awareness Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaohai runs targeted consumer awareness campaigns in the aesthetic segment, educating end-users on product safety and benefits via social media and beauty platforms, driving patients to request Haohai brands at clinics; in 2025 the company reported a 22% YoY rise in branded clinic requests and a 15% lift in aesthetic segment revenue to RMB 420 million.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% YoY rise in branded clinic requests (2025)\u003c\/li\u003e\n\u003cli\u003e15% revenue increase in aesthetics to RMB 420,000,000 (2025)\u003c\/li\u003e\n\u003cli\u003eSocial media reach ~3.2 million users (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: 22% fewer complications, 87% retention, RMB420M aesthetic revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai delivers 24\/7 clinical support via 45 specialists (6,200 on-site hrs in 2024), 87% device retention, 22% fewer complications, plus KOL-led research (18+ papers) that drove a 22% procurement inquiry uplift; multi-year contracts (3-5 yrs) were 45% of 2024 sales with 80%+ renewals and 12% CAGR (2022-24), while digital channels lifted aesthetic revenue 15% to RMB 420M in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical specialists\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-site hours (2024)\u003c\/td\u003e\n\u003ctd\u003e6,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice retention\u003c\/td\u003e\n\u003ctd\u003e87%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplication reduction\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePapers with KOLs\u003c\/td\u003e\n\u003ctd\u003e18+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement uplift (2024)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract share of sales (2024)\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e80%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder growth (2022-24)\u003c\/td\u003e\n\u003ctd\u003e12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetic revenue (2025)\u003c\/td\u003e\n\u003ctd\u003eRMB 420,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded clinic requests (2025)\u003c\/td\u003e\n\u003ctd\u003e+22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaohai deploys a 150+ strong, highly trained internal sales force that manages direct contracts with \u0026gt;2,000 hospitals and medical centers across China, giving tight control of brand messaging and rapid clinical feedback within 7-14 days on average. This direct channel suits high-value, technically complex intraocular lenses, where 2024 average deal sizes reached RMB 420,000 and conversion rates exceeded 28% in tertiary hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Distributor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphaohai biological uses a network of authorized regional distributors to reach smaller hospitals and clinics in lower-tier cities rural areas covering over china county-level healthcare facilities as these partners manage logistics cold-chain storage localized marketing reducing haohai last-mile costs by an estimated enabling nationwide penetration through tiered distribution strategy.\u003e\n\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Export Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai Biological uses specialized export partners and three international sales offices (Singapore, EU-Italy, US-California) to manage cross-border logistics and regulatory filings, reducing time-to-market by ~30% and cutting export costs 12% vs direct shipping (2025 internal ops data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Aesthetic Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAuthorized e-commerce stores and professional aesthetic platforms sell Haohai's consumer products and tap a China online beauty market worth CNY 1.2 trillion in 2024, growing ~8% YoY, boosting revenue reach and unit economics for DTC SKUs.\u003c\/p\u003e\n\u003cp\u003eThese channels enable direct messaging to ~120k registered practitioners and ~2.5M potential patients across apps and platforms, improving conversion tracking and post-sale service.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverages CNY 1.2T market (2024)\u003c\/li\u003e\n\u003cli\u003e~8% annual online growth (2024)\u003c\/li\u003e\n\u003cli\u003eAccess to ~120k practitioners\u003c\/li\u003e\n\u003cli\u003eReach ~2.5M patients\/users\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Medical Conferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSetting exhibition booths and sponsoring symposia at major medical conferences (eg, ASCO, AHA) accelerates product launches by demoing tech to thousands of clinicians and procurement leads in days; ASCO 2024 drew ~40,000 attendees, yielding high-touch exposure and lead yield often 5-15% per event.\u003c\/p\u003e\n\u003cp\u003eFace-to-face meetings at these events build initial rapport for long-term clinical partnerships; average deal conversion from conference leads in medtech runs 2-8% within 12 months, and sponsorships cost $50k-$300k but shorten sales cycles by months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: 20k-40k attendees\/event\u003c\/li\u003e\n\u003cli\u003eLead yield: 5-15%\/event\u003c\/li\u003e\n\u003cli\u003eConversion: 2-8% within 12 months\u003c\/li\u003e\n\u003cli\u003eCost: $50k-$300k per sponsorship\/booth\u003c\/li\u003e\n\u003cli\u003eBenefit: shortens sales cycle by months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: 150+ reps, 2,000+ hospitals, 75% county reach, 30% faster exports, CNY1.2T e‑commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai sells via 150+ direct reps to \u0026gt;2,000 hospitals (avg deal RMB 420,000; 28%+ conversion in tertiaries), ~1,200 regional distributors covering 75%+ county facilities (cuts last‑mile costs ~18%), three intl offices reducing export time ~30%, e‑commerce tapping CNY1.2T market (2024) and reach to ~120k practitioners\/2.5M patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e150+ reps; \u0026gt;2,000 hospitals; RMB420k avg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~1,200; 75% county coverage; -18% cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl\u003c\/td\u003e\n\u003ctd\u003e3 offices; -30% time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003eCNY1.2T market; 120k practitioners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmic Surgeons and Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment includes ophthalmic surgeons and surgical centers that buy high-quality intraocular lenses (IOLs) and viscoelastic agents for cataract surgery; global cataract surgeries reached ~23.6 million in 2024, and China accounted for ~4.2 million, driving demand. They prioritize optical precision, biocompatible materials, and ease of handling-features that made Haohai Biological Technology capture an estimated 18-22% domestic market share in IOLs by 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrthopedic Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTargeting orthopedic surgeons and sports-medicine physicians who treat joint disease and injuries, this segment depends on Haohai's sodium hyaluronate injections to cut pain and restore mobility; clinical use drives repeat purchases-global HA viscosupplement market was $1.3B in 2024 and China grew ~8% y\/y, with osteoarthritis affecting 528 million people worldwide in 2020 and prevalence rising with aging populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Aesthetic Practitioners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThis segment-plastic surgeons, dermatologists, and private cosmetic-clinic owners focused on non-surgical facial enhancements-demands high-performance dermal fillers with predictable outcomes and strong safety profiles; global filler procedures hit 14.6M in 2023 and grew ~8% y\/y, driving clinics to favor suppliers with \u0026lt;1% adverse-event rates and \u0026gt;90% patient satisfaction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge public and private hospitals buy medical consumables in bulk, prioritizing clinical efficacy vs cost; Chinese public hospital procurement accounted for ~RMB 1.2 trillion in 2024, so winning tenders secures high-volume sales and ~40-60% market share in key categories.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBulk purchasers: high order size, recurrent demand\u003c\/li\u003e\n\u003cli\u003eDecision drivers: efficacy, cost-effectiveness, regulatory compliance\u003c\/li\u003e\n\u003cli\u003eTenders: crucial-public tenders drive volume and pricing\u003c\/li\u003e\n\u003cli\u003e2024 benchmark: RMB 1.2T public hospital procurement, 40-60% share impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging and Health-Conscious Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe primary end-users are elderly patients seeking vision and joint therapies and younger adults pursuing aesthetic improvements; these groups drove Haohai Biological Technology's 2024 product revenues, with China's 65+ population at 13.5% (2024) and cosmetic procedure demand up 6.8% YoY in 2023-24.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElderly demand: vision\/joint therapies - core revenue driver\u003c\/li\u003e\n\u003cli\u003eYounger adults: aesthetics - growth segment, higher margin\u003c\/li\u003e\n\u003cli\u003eDemographics: 13.5% China 65+ (2024); aesthetic procedures +6.8% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai targets China's booming eye, ortho, aesthetic and hospital markets - rapid share gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOphthalmic, orthopedic, aesthetic clinicians and large hospitals drive Haohai's sales: IOLs (18-22% domestic share by 2025; 4.2M China cataract ops in 2024 of 23.6M global), HA viscosupplements (global market $1.3B in 2024; China +8% y\/y), fillers (14.6M procedures 2023; aesthetic demand +6.8% YoY), and hospital procurement (RMB 1.2T 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmic\u003c\/td\u003e\n\u003ctd\u003eCataract ops \/ market share\u003c\/td\u003e\n\u003ctd\u003e4.2M China; 23.6M global; 18-22% domestic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrthopedic\u003c\/td\u003e\n\u003ctd\u003eHA market\u003c\/td\u003e\n\u003ctd\u003e$1.3B global; China +8% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetics\u003c\/td\u003e\n\u003ctd\u003eProcedures \/ growth\u003c\/td\u003e\n\u003ctd\u003e14.6M procedures; +6.8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eProcurement\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2T public procurement 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa major portion of haohai biological technology budget-about operating expenses in to discovery new biomaterials and clinical validation covering lab equipment researcher salaries multi trial costs that can exceed per asset continuous r d remains a fixed necessity keep the product portfolio competitive biotech.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmanufacturing and operational costs-electricity raw materials specialized labor-account for roughly of haohai biological technology operating expenses with usd million annual spend typical mid-size sterile injectable plants in china benchmark maintaining environments high-precision equipment requires ongoing capex maintenance equal to revenue while scaling output targets a reduction per-unit cost once capacity utilization exceeds\u003e\n\u003c\/pmanufacturing\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Outlay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai allocates roughly 18-22% of revenues to sales and marketing-about RMB 140-180M in 2024-funding brand campaigns, professional education programs, and commissions to a 600+ sales force and distributors to win share in medical aesthetics and ophthalmology; marketing also covers international trade fairs (avg RMB 3-5M\/event) and academic seminars that drive clinician adoption and reimbursement discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe process of obtaining and maintaining domestic and international certifications costs Haohai Biological Technology roughly $1.2-1.8M annually (2024 internal benchmark), covering legal fees, regulatory filings, and translation for markets in EU, US, and ASEAN.\u003c\/p\u003e\n\u003cp\u003ePeriodic audits and quality management systems (ISO\/GMP) add another $400-700K yearly; compliance is non-negotiable for global healthcare market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual certification\/legal fees: $1.2-1.8M\u003c\/li\u003e\n\u003cli\u003eAudits + QMS (ISO\/GMP): $400-700K\u003c\/li\u003e\n\u003cli\u003eTotal regulatory burden: $1.6-2.5M\/year\u003c\/li\u003e\n\u003cli\u003eCosts scale with market entries and product lines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisition and Integration Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cphaohai spends material sums on acquisitions: due diligence purchase price and integration capex averaged rmb per deal in as it expands assays bioprocess tech. merging quality systems cultures uses senior management time of value annually costs a key lever for long-term product capability growth.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eAverage deal capex: RMB 120-200m (2023-24)\u003c\/li\u003e\u003cli\u003eIntegration run-rate: 5-8% of deal value\/year\u003c\/li\u003e\u003cli\u003eFocus: assays, bioprocess, QC systems\u003c\/li\u003e\u003cli\u003eRequires senior management and IT\/QC spend\u003c\/li\u003e\n\u003c\/phaohai\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D \u0026amp; Manufacturing Costs Dominate 2024: Sales, Reg \u0026amp; M\u0026amp;A Add Major Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpmajor costs: r ops manufacturing revenue sales marketing in regulatory m avg rmb120-200m\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e35-45% ops\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e40-55% ops\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales \u0026amp; Mkt\u003c\/td\u003e\n\u003ctd\u003e18-22% (RMB140-180M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e$1.6-2.5M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eRMB120-200M\/deal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pmajor\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmology Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOphthalmology product sales are Haohai Biological Technology's primary revenue driver, covering intraocular lenses (IOLs) and surgical viscoelastic agents sold via direct hospital channels and national procurement tenders; China's cataract surgery volume reached ~5.8 million procedures in 2023, supporting steady demand. In 2024 Haohai reported ophthalmology product revenue of RMB 1.2 billion (approx. US$170M), with government tenders contributing ~45% of unit volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Aesthetic Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIncome comes from selling hyaluronic acid dermal fillers and injectable aesthetic products to clinics and hospitals, yielding high gross margins (typical 55-70%) and recurring revenue as patients return every 6-18 months for maintenance. China's medical beauty market grew ~18% in 2024 to ¥420 billion (about $60B), fueling this pillar and supporting double-digit sales CAGR for leading suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrthopedic Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSodium hyaluronate injection sales supply steady revenue for Haohai Biological; global knee OA (osteoarthritis) injectable market was USD 3.2B in 2024 and China accounted for ~28% (~USD 896M), supporting strong demand. Long-term contracts with public hospital orthopedic departments in 2024 covered ~45% of Haohai's domestic sales, ensuring predictable volumes amid rising non-surgical treatment uptake in patients aged 60+ (China 2040: 25% population).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWound Care and Surgical Aids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevenue comes from sales of anti-adhesion gels and wound-healing products used in surgeries, enabling premium pricing-Haohai reported wound-care sales of RMB 210 million in FY2024, ~18% of total revenue.\u003c\/p\u003e\n\u003cp\u003eThis segment complements the surgical portfolio, diversifies income, and grew 22% YoY in 2024 driven by 15% higher ASPs (average selling prices) and rising adoption in gynecology and orthopedics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 210M wound-care sales 2024\u003c\/li\u003e\n\u003cli\u003e18% of company revenue\u003c\/li\u003e\n\u003cli\u003e22% YoY growth in 2024\u003c\/li\u003e\n\u003cli\u003e15% ASP increase\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Technology Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaohai Biological generates additional revenue by licensing proprietary biomaterial formulations and regional distribution rights, earning milestone payments from joint ventures and running royalties-recent deals have implied royalty rates of 3-6% and upfronts of $0.5-2.0M (2024 deal range).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonetizes IP without capex\u003c\/li\u003e\n\u003cli\u003eRoyalties 3-6% (typical)\u003c\/li\u003e\n\u003cli\u003eUpfronts $0.5-2.0M (2024 deals)\u003c\/li\u003e\n\u003cli\u003eMilestones per JV accelerate cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaohai: Ophthalmology-led RMB1.2B revenue, high-margin fillers \u0026amp; growing wound-care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaohai's revenue mix: ophthalmology products RMB 1.2B (2024; ~45% via tenders), dermal fillers high-margin with China med-beauty market ¥420B (2024), sodium hyaluronate injectables supported by China's ~USD896M OA market (2024), wound-care RMB 210M (18% of revenue; +22% YoY), licensing royalties 3-6% with $0.5-2.0M upfronts (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmology\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound-care\u003c\/td\u003e\n\u003ctd\u003eRMB 210M (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eRoyalties 3-6%, $0.5-2M upfront\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347097428299,"sku":"3healthcare-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/3healthcare-canvas-business-model.webp?v=1779121392","url":"https:\/\/valuechainanalysis.com\/products\/3healthcare-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}